The estimated Net Worth of Cedric Francois is at least $31.6 Million dollars as of 1 March 2024. Cedric Francois owns over 250,000 units of Apellis Pharmaceuticals Inc stock worth over $21,622,074 and over the last 5 years he sold APLS stock worth over $5,678,661. In addition, he makes $4,267,180 as President, Chief Executive Officer, Co-Founder, and Director at Apellis Pharmaceuticals Inc.
Sign up
Cedric Francois APLS stock SEC Form 4 insiders trading
Cedric has made over 36 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of APLS stock worth $1,050,000 on 1 March 2024.
The largest trade he's ever made was exercising 300,000 units of Apellis Pharmaceuticals Inc stock on 1 September 2023 worth over $801,000. On average, Cedric trades about 33,190 units every 34 days since 2019. As of 1 March 2024 he still owns at least 563,662 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Cedric Francois stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cedric Francois biography
Dr. Cedric Francois M.D. Ph.D. serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois serves on the board of directors of Liberate Medical, Inc., a private medical device company, and, until July 2019, served on the board of directors of Revon Systems, Inc., or Revon, a private healthcare software company which he cofounded. Dr. Francois served as President and Chief Executive Officer of Potentia from 2001 to 2018. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France. Francois is qualified to serve on our board of directors because of his expertise and extensive leadership experience in immunology and immune system-mediated diseases and his extensive knowledge of our company based on his role as co-founder and Chief Executive Officer.
What is the salary of Cedric Francois?
As the President, Chief Executive Officer, Co-Founder, and Director of Apellis Pharmaceuticals Inc, the total compensation of Cedric Francois at Apellis Pharmaceuticals Inc is $4,267,180. There are no executives at Apellis Pharmaceuticals Inc getting paid more.
How old is Cedric Francois?
Cedric Francois is 47, he's been the President, Chief Executive Officer, Co-Founder, and Director of Apellis Pharmaceuticals Inc since 2016. There are 16 older and 4 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
What's Cedric Francois's mailing address?
Cedric's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Insiders trading at Apellis Pharmaceuticals Inc
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
What does Apellis Pharmaceuticals Inc's logo look like?
Complete history of Cedric Francois stock trades at Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc executives and stock owners
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Cedric Francois,
President, Chief Executive Officer, Co-Founder, Director -
Lukas Scheibler,
Chief Innovation Officer -
Federico Grossi,
Chief Medical Officer -
Thomas Lackner,
Senior Vice President, Head of Europe -
Pascal Deschatelets,
Co-Founder, Chief Operating Officer -
Timothy Sullivan,
Chief Financial Officer, Treasurer -
Dr. Cedric Francois,
Co-Founder, Pres, CEO & Director -
Timothy E. Sullivan,
Chief Financial Officer -
Dr. Pascal Deschatelets Ph.D.,
Co-Founder & Chief Scientific Officer -
Adam J. Townsend,
Chief Commercial Officer -
Gerald Chan,
Independent Chairman of the Board -
Stephanie O'Brien,
Independent Director -
Alec Machiels,
Independent Director -
A. Sinclair Dunlop,
Independent Director -
Alec Machiels J.D., MBA,
Co-Founder & Independent Director -
Sam Martin,
IR Contact Officer -
Paul Fonteyne,
Independent Director -
Adam Townsend,
Chief Commercial Officer -
David Watson,
General Counsel, Vice President of Corporate Development -
Nicole Perry,
Vice President - Finance -
Victoria Brown,
Senior Vice President, Program Team Lead – Systemic Chronic -
David O. Watson,
Gen. Counsel -
Meredith Kaya,
Sr. VP, Investor Relations & Strategic Fin. -
James G. Chopas CPA,
VP, Corp. Controller & Chief Accounting Officer -
Dr. Lukas Scheibler M.D., Ph.D.,
Chief Innovation Officer -
Karen Lewis,
Chief People Officer -
Nur Nicholson,
Chief Technical Operations Officer -
Dr. Federico Grossi M.D., Ph.D.,
Co-Founder & Chief Medical Officer -
Nur Nicholson,
Chief Technical Officer -
Karen Lewis,
Chief People Officer -
Venture Investments Ltd Mor...,
10% owner -
Lucia Celona,
See Remarks -
Ahmad Sadr,
See Remarks -
Jeffrey Eisele,
Chief Development Officer -
Mark Jeffrey De Long,
Chief Business & Strat Officer -
James George Chopas,
VP/Chief Accounting Officer -
Caroline Baumal,
Chief Medical Officer